由串联合成的5型和24型链球菌M蛋白的杂交肽拷贝诱发的调理素抗体。
Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem.
作者信息
Beachey E H, Gras-Masse H, Tarter A, Jolivet M, Audibert F, Chedid L, Seyer J M
出版信息
J Exp Med. 1986 Jun 1;163(6):1451-8. doi: 10.1084/jem.163.6.1451.
Abstract
The protective immunogenicity of a hybrid peptide containing tandem copies of types 5 and 24 epitopes was investigated. Carboxy-terminal peptides of the cyanogen bromide-derived fragment 7 (CB7) of type 24 M protein were chemically synthesized, and then extended to include the first 20 residues of the amino-terminus of type 5 M protein. When emulsified in CFA and injected into rabbits without conjugation to a carrier, each of the synthetic hybrid peptides, designated S-M5(1-20)-S-CB7(23-35)C and S-M5(1-20)-S-CB(19-34), evoked opsonic antibodies against both types 5 and 24 streptococci without raising heart tissue-crossreactive immunity. These results suggest that tandem hybrid peptides may provide a new approach to the development of multivalent vaccines, not only to different serotypes of group A streptococci but perhaps also to a variety of other infectious agents.
摘要
研究了含有5型和24型表位串联拷贝的杂合肽的保护性免疫原性。化学合成了24型M蛋白的溴化氰衍生片段7（CB7）的羧基末端肽，然后进行延伸，使其包含5型M蛋白氨基末端的前20个残基。当在弗氏完全佐剂中乳化并注射到未与载体偶联的兔体内时，每种合成杂合肽，即S-M5(1-20)-S-CB7(23-35)C和S-M5(1-20)-S-CB(19-34)，均可诱导产生针对5型和24型链球菌的调理素抗体，且不会引发心脏组织交叉反应性免疫。这些结果表明，串联杂合肽可能为开发多价疫苗提供一种新方法，不仅可用于A组链球菌的不同血清型，或许还可用于多种其他感染因子。
相似文献
1
Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem.由串联合成的5型和24型链球菌M蛋白的杂交肽拷贝诱发的调理素抗体。
J Exp Med. 1986 Jun 1;163(6):1451-8. doi: 10.1084/jem.163.6.1451.
2
Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.多价A群链球菌疫苗，旨在优化六个串联M蛋白片段的免疫原性。
Vaccine. 1999 Jan;17(2):193-200. doi: 10.1016/s0264-410x(98)00150-9.
3
Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem.串联合成的包含5型、6型和24型M蛋白氨基末端序列的三价杂合肽的保护性免疫原性和T淋巴细胞特异性。
J Exp Med. 1987 Sep 1;166(3):647-56. doi: 10.1084/jem.166.3.647.
4
Synthetic peptide fragments of streptococcal M proteins.链球菌M蛋白的合成肽片段
Dev Biol Stand. 1986;63:101-8.
5
Protective and heart-crossreactive epitopes located within the NH2 terminus of type 19 streptococcal M protein.位于19型链球菌M蛋白NH2末端的保护性和心脏交叉反应性表位。
J Exp Med. 1988 Jun 1;167(6):1849-59. doi: 10.1084/jem.167.6.1849.
6
Recombinant tetravalent group A streptococcal M protein vaccine.重组A群链球菌M蛋白四价疫苗
J Immunol. 1993 Aug 15;151(4):2188-94.
7
Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein.5型链球菌M蛋白氨基末端保护性表位的定位
J Exp Med. 1986 May 1;163(5):1191-202. doi: 10.1084/jem.163.5.1191.
8
Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein.链球菌M蛋白化学合成的13、18和23个氨基酸残基肽片段的表位特异性保护性免疫原性。
Proc Natl Acad Sci U S A. 1984 Apr;81(7):2203-7. doi: 10.1073/pnas.81.7.2203.
9
10
Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.5型链球菌M蛋白化学合成肽片段的型特异性免疫原性
J Exp Med. 1983 Nov 1;158(5):1727-32. doi: 10.1084/jem.158.5.1727.
引用本文的文献
1
: Pathogenesis and the Current Status of Vaccines.发病机制与疫苗的现状
Vaccines (Basel). 2023 Sep 21;11(9):1510. doi: 10.3390/vaccines11091510.
2
Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.A组链球菌感染：其机制、流行病学及疫苗的当前应用范围
Cureus. 2022 Dec 30;14(12):e33146. doi: 10.7759/cureus.33146. eCollection 2022 Dec.
3
Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.疫苗接种预防 A 组链球菌咽炎的方法。
Microbiol Spectr. 2019 May;7(3). doi: 10.1128/microbiolspec.GPP3-0010-2018.
4
Development of Phage Lysins as Novel Therapeutics: A Historical Perspective.噬菌体裂解酶的开发作为新型治疗方法：历史视角。
Viruses. 2018 Jun 7;10(6):310. doi: 10.3390/v10060310.
5
Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.由包含10株表达源自A组链球菌的高度流行M蛋白抗原的乳酸乳球菌菌株的鼻内多价疫苗诱导的保护性免疫。
Microbiol Immunol. 2018 Jun;62(6):395-404. doi: 10.1111/1348-0421.12595. Epub 2018 Jun 11.
6
A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.一种新型的经鼻内接种的A群9型链球菌活载体疫苗可保护小鼠免受9型A群链球菌的攻击感染。
Clin Vaccine Immunol. 2014 Sep;21(9):1343-9. doi: 10.1128/CVI.00330-14. Epub 2014 Jul 23.
7
Disease manifestations and pathogenic mechanisms of Group A Streptococcus.A 组链球菌的疾病表现及致病机制
Clin Microbiol Rev. 2014 Apr;27(2):264-301. doi: 10.1128/CMR.00101-13.
8
Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.来自澳大利亚原住民分离株和A组链球菌参考菌株的M蛋白氨基末端的保护性和非保护性表位。
Infect Immun. 2000 Dec;68(12):6587-94. doi: 10.1128/IAI.68.12.6587-6594.2000.
9
Pathogenesis of group A streptococcal infections.A组链球菌感染的发病机制。
Clin Microbiol Rev. 2000 Jul;13(3):470-511. doi: 10.1128/CMR.13.3.470.
10
Protective immunity evoked by oral administration of attenuated aroA Salmonella typhimurium expressing cloned streptococcal M protein.口服表达克隆链球菌M蛋白的减毒鼠伤寒沙门氏菌aroA菌株所诱发的保护性免疫。
J Exp Med. 1988 Jul 1;168(1):25-32. doi: 10.1084/jem.168.1.25.
本文引用的文献
1
Current knowledge of type-specific M antigens of group A streptococci.A组链球菌特定类型M抗原的现有知识。
J Immunol. 1962 Sep;89:307-13.
2
Streptococcal M protein: alpha-helical coiled-coil structure and arrangement on the cell surface.链球菌M蛋白：α-螺旋卷曲螺旋结构及其在细胞表面的排列
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4689-93. doi: 10.1073/pnas.78.8.4689.
3
Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein.链球菌M蛋白化学合成的13、18和23个氨基酸残基肽片段的表位特异性保护性免疫原性。
Proc Natl Acad Sci U S A. 1984 Apr;81(7):2203-7. doi: 10.1073/pnas.81.7.2203.
4
Antibody responses elicited by a polyvalent vaccine containing synthetic diphtheric, streptococcal and hepatitis peptides coupled to the same carrier.由一种多价疫苗引发的抗体反应，该疫苗含有与同一载体偶联的合成白喉、链球菌和肝炎肽。
Biochem Biophys Res Commun. 1983 Dec 28;117(3):908-15. doi: 10.1016/0006-291x(83)91682-0.
5
Repeating covalent structure and protective immunogenicity of native and synthetic polypeptide fragments of type 24 streptococcal M protein. Mapping of protective and nonprotective epitopes with monoclonal antibodies.24型链球菌M蛋白天然及合成多肽片段的重复共价结构与保护性免疫原性。用单克隆抗体对保护性和非保护性表位进行定位。
J Biol Chem. 1983 Nov 10;258(21):13250-7.
6
Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant.由无载体或佐剂的合成链球菌抗原引发的表位特异性免疫。
Biochem Biophys Res Commun. 1983 Dec 16;117(2):359-66. doi: 10.1016/0006-291x(83)91208-1.
7
Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.5型链球菌M蛋白化学合成肽片段的型特异性免疫原性
J Exp Med. 1983 Nov 1;158(5):1727-32. doi: 10.1084/jem.158.5.1727.
8
Protective antigenic determinant of streptococcal M protein shared with sarcolemmal membrane protein of human heart.与人心肌细胞膜蛋白共有的链球菌M蛋白保护性抗原决定簇。
J Exp Med. 1982 Oct 1;156(4):1165-76. doi: 10.1084/jem.156.4.1165.
9
Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein.化脓性链球菌M蛋白合成肽引发的型特异性保护性免疫
Nature. 1981 Jul 30;292(5822):457-9. doi: 10.1038/292457a0.
10
Primary structure of protective antigens of type 24 streptococcal M protein.24型链球菌M蛋白保护性抗原的一级结构
J Biol Chem. 1980 Jul 10;255(13):6284-9.
Zotero 插件